The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

The lab of Dr. Mark Magnuson, Louise B. McGavock Professor and professor of molecular physiology and biophysics at Vanderbilt ...

Cite this: The Intestinal Absorption of Biliary and Dietary Cholesterol as a Drug Target for Lowering the Plasma Cholesterol Level - Medscape - Jan 01, 2003.

Analysis of clinically actionable alterations in baseline tumor versus plasma samples in participants of the TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer ...

The Biliary Atresia market growth is driven by factors like increase in the prevalence of Biliary Atresia, investments in ...

Radiomics-based prediction of HCC response to atezolizumab/bevacizumab. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal of Clinical Oncology show that chemotherapy combining three different ...

Biliary tract cancer occurs in the bile ducts ... had more good news with the drug today from a clinical trial in renal cell carcinoma, a form of kidney cancer. In the KEYNOTE-564 study, Keytruda ...